EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk

Jan Kafol, Borut Jug iD, Zlatko Fras iD

Cells · 20.07.2026 · 15 (14) · 1293

DOI: 10.3390/cells15141293 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 20.07.2026. Verfasst von Jan Kafol und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Obesity, Inflammation, Incretins, Atherosclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular disease remains a leading cause of mortality despite major advances in lipid lowering and risk-factor control, highlighting the importance of residual cardiovascular risk. Inflammation is a central driver of atherosclerosis, while obesity promotes chronic low-grade inflammation, adipose tissue dysfunction, ectopic fat accumulation, and vascular injury. This narrative review focuses on obesity-associated inflammation as an upstream contributor to residual atherosclerotic risk and evaluates whether incretin-based therapies modify this pathway through weight loss, metabolic improvement, and additional inflammatory or vascular mechanisms. Data from mechanistic studies, biomarker analyses, vascular imaging studies, and cardiovascular outcome trials are reviewed. Anti-inflammatory trials support inflammation as a modifiable therapeutic pathway, although clinical benefit depends on the therapeutic target, timing, and patient selection. Glucagon-like peptide-1 receptor agonists reduce inflammatory and oxidative stress biomarkers and show anti-atherosclerotic effects in experimental models, but human vascular imaging data remain inconclusive. Cardiovascular outcome trials establish benefit with several GLP-1 receptor agonists, including semaglutide in selected patients with overweight or obesity without diabetes. However, direct human evidence for receptor-mediated anti-inflammatory or anti-atherosclerotic effects remains limited, and the relative contributions of weight loss, metabolic improvement, and additional mechanisms remain uncertain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityInflammationIncretinsAtherosclerosisHumansAnimalsSemaglutideRisk Factors

Stichwörter der Autor:innen

adipose tissue inflammationatherosclerosiscardiovascular preventionglucagon-like peptide-1 receptor agonistsincretin-based therapyinflammationobesityresidual inflammatory risksemaglutidetirzepatide

Substanzen

IncretinsSemaglutide

Autor:innen und Institutionen

  • Department of Vascular Diseases, Division of Internal Medicine, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
  • Faculty of Medicine, University of Ljubljana, 1000 Ljubljana, Slovenia.

ORCID-Profile: Borut Jug, Zlatko Fras

Förderung

  • The Slovenian Research and Innovation Agency

Zitieren

APA

Kafol, J., Jug, B., & Fras, Z. (2026). Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk. Cells, 15(14), 1293. https://doi.org/10.3390/cells15141293

Vancouver

Kafol J, Jug B, Fras Z. Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk. Cells. 2026;15(14):1293. doi:10.3390/cells15141293

BibTeX
@article{Kafol2026,
  author = {Kafol, Jan and Jug, Borut and Fras, Zlatko},
  title = {Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {14},
  pages = {1293},
  doi = {10.3390/cells15141293}
}
Kostenlos starten →